Most recent by Gil Yosipovitch, MD
Remibrutinib safe, effective for chronic spontaneous urticaria over 52 weeks
Patients with chronic spontaneous urticaria showed rapid symptom improvement with a favorable safety profile over 52 weeks of treatment with remibrutinib, according to a study published in The Journal of Allergy and Clinical Immunology.
Adults, children with chronic spontaneous urticaria differ in clinical features, response
Pediatric and adult chronic spontaneous urticaria exhibit distinct features, with adolescent presentations resembling those of adults more than those of younger children, according to a study published in Pediatric Allergy and Immunology.
Adults taking dupilumab for atopic dermatitis also see improvements in mild asthma
Adults who were taking dupilumab for their atopic dermatitis also experienced significant improvements in their mild asthma, primarily in the first 16 weeks, according to a study published in Clinical and Translational Allergy.
Remibrutinib ‘very effective’ in treating moderate to severe chronic spontaneous urticaria
Remibrutinib appeared very effective in treating moderate to severe chronic spontaneous urticaria, with a rapid onset of action and a favorable safety profile, according to a study published in The Journal of Allergy & Clinical Immunology.
Dupixent approved for prurigo nodularis treatment
The FDA has approved Dupixent for the treatment of prurigo nodularis in adults, Regeneron and Sanofi announced in a press release.